Recently, the industrial base construction projects of sucralose, dietary supplements and daily chemical ingredients of Fujian Kehong Bioengineering Co., Ltd. started trial production. This project is a provincial key project, covering an area of 223 mu, with a total investment of 500 million yuan. After all put into production, the sales revenue can be increased by 654.38 billion yuan, and the profit and tax can be more than 200 million yuan.

In recent years, our city has seized the opportunity of development, relying on rich medicinal plant resources, characteristic pharmaceutical products and professional parks, and taking Kehong Bio, Nanfang Pharmaceutical and other enterprises as the leading enterprises to build a biomedical industry gathering platform with Sanming advantages and characteristics. In the first three quarters, the added value of 57 biomedical enterprises above designated size increased by 6.6%, and the industrial added value increased by 4.4 percentage points.

Guided by the project, the city drew the investment map of biomedical industry, focusing on the projects of China Resources Traditional Chinese Medicine Industrial Park, research and development and production of pharmaceutical intermediates containing fluoropyridine, and annual output of 1 10 of medical contrast agent series products, and promoting the completion and commissioning of Fujian Xihua Pharmaceutical Industrial Park and Mingxi Wolin Dajian Health Series products.

Our city will hold international cooperation in biomedical industry? Join hands to take the opportunity of thematic docking activities, and invite AstraZeneca, Takeda, Roche Pharmaceutical, Novartis and other 12 world-renowned multinational pharmaceutical companies to cooperate with 15 local biopharmaceutical companies to seek common development of the industry, and sign a strategic cooperation agreement with the Biotechnology Innovation Committee of China Association of Enterprises with Foreign Investment.

At present, there are 223 drug production batch numbers in the city, including Class I and Class II new drugs 1 each, Class III new drugs/0/each, exclusive national varieties/5, and confidential prescriptions 1 each. 66 medical devices and diagnostic reagents registration certificate; There are more than 500 kinds of Chinese herbal pieces; There are 19 approvals for APIs. The domestic market share of taxane anti-tumor APIs produced by Southern Pharmaceutical and Taxus Garden is about 70%, that of hexafluoroisopropyl methyl ether produced by Hayford is 100%, and that of hexafluoroisopropanol is 90%. (Zhu, Xiao, Zhai Zhenjun)